Navigation Links
Intrinsic Enrolls First Patient in Barricaid® Trial
Date:2/17/2011

WOBURN, Mass., Feb. 17, 2011 /PRNewswire/ -- Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid® device. Barricaid is designed to prevent reherniations following lumbar discectomy, while allowing the surgeon to retain as much of the native nucleus as possible preserving normal disc height and biomechanics. Barricaid accomplishes this by providing the added security of a bone-anchored device that can be used to close larger anular defects or in cases where anular integrity is in question.

The procedure was performed by Guido Dua, M.D., Chief of Neurosurgery, Middelheim Hospital in Antwerp, Belgium. Robert Hes, MD, Principal Investigator at Middelheim, stated, "What I like about the Barricaid device is that it provides an elegant solution to possible reherniation. Barricaid allows for a limited discectomy while offering the potential for secure closure of the anular defect and a reduction in both the risk of recurrent disc herniation and disc height loss.  I was very satisfied with the simplicity and ease of the procedure. I anticipate that we will be able to recreate the outstanding results seen in prior Barricaid studies."

"We are pleased to have begun our randomized study in Europe," said Noel Rolon, Intrinsic Vice President, Regulatory and Clinical Affairs. "The fact that we have started enrolling patients so quickly indicates the level of enthusiasm among our investigators.  It is clear that the positive clinical and commercial results recently presented at the DWG meeting in Bremen and published in the November 2010 issue of the European Spine Journal, provide a strong foundation for this post-marketing study."

Intrinsic is enrolling up to 800 patients in a prospective, randomized, superiority study comparing Barricaid to traditional limited discectomy. "We are exc
'/>"/>

SOURCE Intrinsic Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
2. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
3. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
4. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial
7. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
8. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
9. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
10. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
11. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... (NASDAQ: VOLC ), a global leader in catheter-based ... they have entered into a definitive merger agreement. Pursuant to ... all of the issued and outstanding shares of Volcano for ... of USD 1 billion (approx. EUR 800 million), to be ...
(Date:12/17/2014)... 17, 2014  Northstar Global Business Services, Inc. ... (DTC) has made their final decision and has ... Company,s stock effective December 15, 2014, and has ... depository and book entry transfer services. All deposit restrictions ... once again fully "DTC Eligible", and has resumed ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, ... US Patent and Trademark Office (USPTO) has issued ... a dendritic cell-based immunotherapeutic vaccine targeting six tumor ... claims of US Patent No. 8,871,211, which issued ... cancer by administering a dendritic cell composition comprising ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Valley Technologies, Inc. (LVT) is pleased to announce ... the U.S. Food and Drug Administration (FDA).  On ... with no Form 483 observations and no discussion ... relating to cGMP (current Good Manufacturing Practices).  Additionally, ...
... MORRISVILLE, N.C., Jan. 9, 2012  nContact, Inc., the ... its technology will be presented by physicians in ... Atrial Fibrillation Symposium, January 12-14 in Boston, Massachusetts. ... with VisiTrax® and next generation EPi-Sense™ Coagulation System ...
Cached Medicine Technology:nContact's Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012 2
(Date:12/19/2014)... December 20, 2014 Today, Balfleet.com ... special-occasion outfits, announces its formal dress promotion. All the ... up to 60% off. , Balfleet.com is well-known for ... bridesmaid dresses, prom dresses, cocktail dresses and more. Its ... 30-day money-back guarantee, and they can create an elegant ...
(Date:12/19/2014)... Energy Textiles is excited to ... Celliant, the world’s leading responsive textile, can now ... There are a number of benefits to wearing ... and balanced body temperature; which can lead to ... enhanced athletic performance; and overall wellness. In addition, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Potentially illness-causing ... herbs bought at farmers markets, according to a new ... almost 50 vendors from 13 farmers markets in Los ... Seattle area. Out of almost 150 samples tested, 24 ... positive for salmonella, according to the researchers. Both ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... the immune cells and incorporating it into the vaccine ... ,Researchers from the University of Pittsburgh have ... patients with HIV, subject their immune system cells through ... in their fight against the disease. Announcing their findings ...
... 12 after no new cases emerged since the February/March outbreak ... its status as an avian influenza free country and a ... Organisation of Animal Health yesterday," said a statement issued by ... bird flu outbreak among poultry on February 18 at Navapur ...
... packaging that contains latex, which will certainly prevent the allergic ... UK showed that nearly a third of food packaging was ... biscuit, the quantity of latex was so high to have ... from the UK Latex Allergy Support Group (LASG) Advisory Panel ...
... good managers and appropriate IT may be a far ... doctors and nurses than recruiting more staff,// according to ... who are against reforming the NHS blame problems on ... judgement, and the “greedy” private sector. But there is ...
... was diagnosed with tuberculosis, precautionary letters have been sent ... of them contracting the// disease. The condition of ... be satisfactory. ,The patient was diagnosed ... to the infectious diseases unit at Aberdeen Royal Infirmary ...
... the breast lesion by taking x-ray of the lesion ... radiologists. "Contrast-enhanced// MRI of the breast is becoming increasingly ... with other techniques," said Basak Erguvan-Dogan, MD, radiologist in ... Cancer Center in Houston. "However, it is hard to ...
Cached Medicine News:Health News:Activated T-Cells Could Help In The Battle Against HIV 2Health News:Activated T-Cells Could Help In The Battle Against HIV 3Health News:Food Packaging Containing Latex May Trigger an Allergic Reaction 2Health News:More and Better Management Is Key to Fixing the NHS 2Health News:MRI-guided Breast Biopsy Pronounced a Success 2
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: